SLC2A1 and cancer: On the other hand, inhibitors selective for one or two GLUT isoforms that predominate in certain cancers, when coupled with other anti-cancer treatments, may provide new therapeutic strategies that adjust depending on the metabolic reprogramming of the cancer type and stage.